<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00895206</url>
  </required_header>
  <id_info>
    <org_study_id>2008/640</org_study_id>
    <nct_id>NCT00895206</nct_id>
  </id_info>
  <brief_title>Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study</brief_title>
  <acronym>CD4-01</acronym>
  <official_title>Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open, randomised trial in which one group of patients (control) will receive
      the golden standard therapy and the other group (treatment) will receive individually adapted
      immunosuppression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft function as measured by Cr EDTA AUC</measure>
    <time_frame>at 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft survival</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft function measured by estimated GFR (eGFR) (MDRD and Cockroft-Gault)</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of biopsy proven acute rejection episodes</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of biopsy proven acute rejection (BPAR) and clinical (non-biopsy proven) acute rejection episodes treated by a full course anti-rejection therapy (e.g. steroids) (Treatment of rejection according to center practice).</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of rejection treated by antibodies (OKT3, ATG)</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first rejection (days)</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of rejection as assessed by BANFF 2005 score</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of acute rejections per patient</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma creatinine and eGFR</measure>
    <time_frame>at month 1, 3 and yearly (2 and 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured GFR</measure>
    <time_frame>at month 3 and yearly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>at month 1, 3 and at 1 and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and score of borderline changes and acute rejection</measure>
    <time_frame>in month 3 and month 12 biopsy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and score of chronic alloimmune injury/rejection and nonimmune injury</measure>
    <time_frame>in month 3 and month 12 biopsies (BANFF 2005)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development and evolution of glucose abnormalities</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ambulatory 24-hr blood pressure monitoring</measure>
    <time_frame>at 1 year and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular mass assessed by echocardiography</measure>
    <time_frame>at 1 year and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting lipid profile</measure>
    <time_frame>at baseline, month 1,3,6 and yearly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMV infection (as measured with whole blood PCR) and disease</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polyoma virus replication as measured by whole blood PCR</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of BK nephritis</measure>
    <time_frame>in month 3 and month 12 biopsies</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of PTLD and Nonmelanoma skin cancer</measure>
    <time_frame>at 1 year and yearly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of EBV reactivation (as measured with whole blood PCR)</measure>
    <time_frame>at 1 year and yearly</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>individual adapted immunosuppression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>golden standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>individual adapted immunosuppression</intervention_name>
    <description>individual adapted immunosuppression</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>golden standard therapy</intervention_name>
    <description>golden standard therapy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First or second kidney transplantation

          -  Males and females, 18 years old or older

          -  Women of childbearing potential must have a negative serum or urine pregnancy test
             with sensitivity equal to at least 50 mIU/mL

          -  Patients must be capable of understanding the purpose and risks of the study and must
             sign an informed consent form

        Exclusion Criteria:

          -  Multiple organ transplantation (eg. kidney-pancreas, kidney-heart, kidney-liver,...)

          -  Transplantation of a patient who received another organ transplant previously except
             one kidney transplant

          -  Recipients of HLA-identical living-related renal transplants

          -  Patients with PRA &gt; 10%, patients who have lost a first graft from rejection.

          -  Pregnant or lactating women

          -  WBC =&lt; 2.5 x 109/L (IU), platelet count =&lt; 100 x 109/L (IU), or Hb =&lt; 6g/dl at the
             time of entry into the study

          -  Active peptic ulcer

          -  Severe diarrhea or other gastrointestinal disorders which might interfere with the
             ability to absorb oral medication, including diabetic patients with previously
             diagnosed diabetic gastroenteropathy

          -  Known HIV-1 or HTLV-1 positive tests

          -  History of malignancy in the past 5 years (with the exception of adequately treated
             basal or squamous skin cell carcinoma)

          -  The use of investigational drugs or other immunosuppressive drugs as those specified
             in this protocol

          -  Patients receiving bile acid sequestrants

          -  Psychological illness or condition interfering with the patient's compliance or
             ability to understand the requirements of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Vanholder, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>website of the University Hospital Ghent</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2009</study_first_submitted>
  <study_first_submitted_qc>May 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2009</study_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

